Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 24, 2015 6:54 PM ET

Biotechnology

Company Overview of Incyte Corporation

Executive Profile

David W. Gryska MBA

Chief Financial Officer and Executive Vice President, Incyte Corporation
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 12 different industries.

See Board Relationships
59$2,308,442
As of Fiscal Year 2014

Background

Mr. David W. Gryska, also known as Dave, MBA, has been the Chief Financial Officer and Executive Vice President of Incyte Corporation since October 31, 2014. Mr. Gryska has been Strategic Advisor to the Board at Novogen Limited since March 3, 2014. Mr. Gryska served as an Interim Chief Executive Officer of Myrexis Inc., from August 15, 2012 to December 24, 2012. He served as the Chief Operating Officer of Myrexis, Inc., from May 11, 2012 to December 24, 2012 and served ...

Corporate Headquarters

1801 Augustine Cut-Off
Wilmington, Delaware 19803

United States

Phone: 302-498-6700
Fax: --

Board Members Memberships

Former Director
Former Director
Director
2004-Present
Independent Director and Chairman of Audit Committee
2005-Present
Director and Chairman of Audit Committee
2010-2014
Former Lead Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee
2012-2014
Former Director, Chairman of Audit Committee and Member of Compensation Committee
2012-2012
Former Interim Chief Executive Officer, President, Chief Operating Officer and Director
2012-2015
Former Director and Member of Audit Committee
2014-Present
Director, Member of Nominating & Governance Committee and Member of Audit Committee

Education

MBA
Golden Gate University
BA
Loyola University of Chicago

Other Affiliations

Annual Compensation

Salary$63,788
Bonus$50,000
Total Annual Compensation$113,788

Stocks Options

Restricted Stock Awards$524,946
All Other Compensation$30,645
Unexercisable Options$55,376
Unexercisable Options Value$335,025
Total Value of Options$335,024
Total Number of Options$55,376

Total Compensation

Total Annual Cash Compensation$208,522
Total Short Term Compensation$113,788
Other Long Term Compensation$555,591
Total Calculated Compensation$2,308,442
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
$854.7K
Harvey J. Berger M.D.Principal Founder, Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Ariad Pharmaceuticals Inc.
$1.4M
Jean-Jacques Bienaime MBAChief Executive Officer and Director
BioMarin Pharmaceutical Inc.
$916.0K
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.1M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$830.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Incyte Corporation, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.